8-K: Mirion Technologies Reports Q3 2024 Results, Updates Full Year Guidance

Mirion Technologies announced an 8.2% increase in revenue for the third quarter of 2024, alongside an updated full-year guidance.

Summary

• Mirion Technologies reported an 8.2% increase in revenue for the third quarter of 2024, reaching $206.8 million compared to $191.2 million in the same period last year.
• The company experienced a net loss of $14.0 million in Q3, slightly higher than the $12.9 million loss in the same quarter of 2023.
• Adjusted EBITDA for the quarter was $45.7 million, a 17.8% increase from $38.8 million in the prior year.
• The loss from operations margin was 0.8%, down from 5.8% in the same period last year, while the adjusted EBITDA margin improved to 22.1% from 20.3%.
• GAAP net loss per share was $0.07, compared to $0.06 in Q3 2023, and adjusted earnings per share was $0.08, up from $0.05.
• Mirion updated its full-year 2024 guidance, now expecting total revenue growth of 6% to 7% and organic revenue growth of 5% to 6%.
• The adjusted free cash flow range was tightened to $65 to $75 million, while adjusted EBITDA and adjusted EPS ranges remain unchanged at $195 to $205 million and $0.37 to $0.42 per share, respectively.

Sentiment

Score: 7

Explanation: The sentiment is positive due to strong revenue growth, improved adjusted EBITDA, and an upward revision of full-year revenue guidance. However, the net loss and reduced free cash flow guidance temper the overall positive outlook.

Positives

• Mirion experienced strong revenue growth in the third quarter, with an 8.2% increase year-over-year.
• The company's adjusted EBITDA increased by 17.8%, indicating improved profitability.
• Adjusted EBITDA margin expanded by 180 basis points, marking the fifth consecutive quarter of margin expansion.
• The company's adjusted earnings per share increased from $0.05 to $0.08 year-over-year.
• Mirion updated its full-year revenue growth guidance upwards, reflecting confidence in future performance.
• The nuclear power adjusted order book increased 12% excluding the impacts from two large, one-time orders in third quarter 2023.

Negatives

• The company reported a net loss of $14.0 million for the third quarter, which is slightly higher than the $12.9 million loss in the same period last year.
• Loss from operations margin decreased to 0.8% from 5.8% in the same period last year.
• The company's GAAP net loss per share was $0.07, compared to $0.06 in the third quarter of 2023.
• The adjusted free cash flow range was tightened to $65 to $75 million, which is a reduction at the top end of the range.

Risks

• The company's forward-looking statements are subject to various risks and uncertainties, including changes in economic conditions, government budgets, and market trends.
• There are risks related to the public's perception of nuclear radiation and nuclear technologies.
• The company faces risks related to competition, supply chain management, and cybersecurity.
• Mirion is exposed to fluctuations in foreign currency exchange rates, interest rates, and inflation.
• The company's ability to realize sales from its backlog of orders and contracts is subject to risk.
• The closure of the lasers business is expected to negatively impact organic revenue growth by approximately 30 basis points.

Future Outlook

Mirion updated its full-year 2024 guidance, expecting total revenue growth of 6% to 7% and organic revenue growth of 5% to 6%. The adjusted free cash flow range was tightened to $65 to $75 million. Adjusted EBITDA and adjusted EPS ranges remain unchanged at $195 to $205 million and $0.37 to $0.42 per share, respectively. The company aims to achieve 30% adjusted EBITDA margins in the long term.

Management Comments

• Thomas Logan, Mirion's Chief Executive Officer, stated that third quarter results were in-line with expectations.
• Logan noted continued revenue growth and margin expansion across both segments, supported by strong underlying super-trends in nuclear power and cancer care.
• Logan highlighted that the nuclear power adjusted order book increased 12% excluding the impacts from two large, one-time orders in third quarter 2023.
• Logan mentioned that the company is well-positioned for future growth due to its strategic relationships with small modular reactor (SMR) players and utility-scale nuclear power providers.
• Logan commented that the adjusted EBITDA margin of 22.1% marks the fifth consecutive quarter of EBITDA margin expansion.
• Logan stated that the company's expected 2024 performance represents improvements in top-line growth, adjusted EBITDA margin expansion, and further improvements to the balance sheet.

Industry Context

The announcement highlights Mirion's position in the radiation detection and measurement market, particularly in the nuclear power and medical sectors. The company is benefiting from increased demand in nuclear power, driven by the need for clean energy and the development of next-generation nuclear power technology. The company's strategic relationships with SMR players and utility-scale nuclear power providers position it well for future growth in this sector. The company also benefits from the growth in cancer care.

Comparison to Industry Standards

• Mirion's revenue growth of 8.2% in Q3 2024 is a solid performance in the radiation detection and measurement industry, which is experiencing growth due to increased demand in nuclear power and medical sectors.
• Companies like Thermo Fisher Scientific and PerkinElmer, which also operate in related scientific and medical equipment markets, have reported similar growth rates in recent quarters, indicating a positive trend in the industry.
• Mirion's adjusted EBITDA margin of 22.1% is competitive with industry benchmarks, although some companies in the medical device sector may have higher margins due to different cost structures and product mixes.
• The company's focus on margin expansion is a positive sign, as it indicates improved operational efficiency and profitability.
• The updated full-year guidance reflects management's confidence in the company's ability to maintain its growth trajectory and achieve its financial targets.

Stakeholder Impact

• Shareholders will likely react positively to the increased revenue and improved adjusted EBITDA, but may be concerned about the net loss and reduced free cash flow guidance.
• Employees may be encouraged by the company's growth and positive outlook.
• Customers will benefit from the company's continued investment in its products and services.
• Suppliers may see increased demand for their products and services.
• Creditors may view the company's financial performance as stable and positive.

Next Steps

• Mirion will host a conference call on October 30, 2024, to discuss its financial results.
• The company will continue to focus on improving operating efficiency and progressing towards its long-term objective of 30% adjusted EBITDA margins.

Key Dates

Keywords

radiation detection, nuclear power, medical, EBITDA, revenue growth, financial results, adjusted EPS, guidance, organic growth, free cash flow